Author
@PersimmonTI PersimmonTI
grade Ax.com/PersimmonTI ↗
Anon biotech specialist who reads trials, IP, and M&A like an insider
Posts original biotech/pharma analysis - clinical-endpoint f
trader score
+0.79
hit rate
60%
mean α
+0.28%
signals 14d
44
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 60% hit rate, +0.28% mean alpha, trader score +0.79. Their last-14d mentions, direction-adjusted, have moved +2.0% since posting (mean over 34 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-15 | SNDX | @PersimmonTI | +0.90 | Author explicitly expresses extreme bullish enthusiasm for SNDX. | · | tweet ↗ |
| 2026-10-15 | VSTM | @PersimmonTI | +0.65 | Author says the VSTM data speak loudly, implying a favorable interpretation. | · | tweet ↗ |
| 2026-10-15 | XBI | @PersimmonTI | +0.35 | Calls for a second dead-cat bounce in biotech ETF. | -0.2% | tweet ↗ |
| 2026-10-15 | XBI | @PersimmonTI | +0.45 | Frames neglected strong biotech data as an opportunity. | -0.2% | tweet ↗ |
| 2026-10-15 | ANL | @PersimmonTI | +0.20 | Expresses interest in an ANL-Lilly biotech development without details. | — | tweet ↗ |
| 2026-10-15 | LLY | @PersimmonTI | +0.20 | Expresses interest in an ANL-Lilly biotech development without details. | +1.7% | tweet ↗ |
| 2026-10-15 | XBI | @PersimmonTI | +0.10 | Expresses interest in an ANL-Lilly biotech development without details. | -0.2% | tweet ↗ |
| 2026-10-14 | VSTM | @PersimmonTI | +0.20 | Hints that VSTM's conference call contained something important but withholds the substance and direction | · | tweet ↗ |
| 2026-10-14 | XBI | @PersimmonTI | +0.00 | Hints that VSTM's conference call contained something important but withholds the substance and direction | +1.9% | tweet ↗ |
| 2026-10-14 | VSTM | @PersimmonTI | +0.75 | Strongly endorses VSTM and its VS-7375 program. | · | tweet ↗ |
| 2026-10-14 | VSTM | @PersimmonTI | +0.65 | Reports strong VS-7375 response rates, durability, tolerability and FDA Phase 3 alignment. | · | tweet ↗ |
| 2026-10-13 | LQDA | @PersimmonTI | +0.45 | Reports a global settlement resolving six lawsuits while preserving YUTREPIA access. | +59.1% | tweet ↗ |
| 2026-10-13 | XBI | @PersimmonTI | +0.10 | Reports a global settlement resolving six lawsuits while preserving YUTREPIA access. | +1.9% | tweet ↗ |
| 2026-10-13 | VSTM | @PersimmonTI | +0.55 | Publishes optimistic predictions for upcoming VS-7375 efficacy and safety data. | · | tweet ↗ |
| 2026-10-13 | XBI | @PersimmonTI | +0.10 | Publishes optimistic predictions for upcoming VS-7375 efficacy and safety data. | +1.9% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.